HIV associated nephropathy epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 6: Line 6:
HIV-associated nephropathy (HIVAN) is mostly seen in male patients and of African decent. The [[prevalence]] of HIVAN in the population of patients with African descent has been reported to be 3% to 12%.
HIV-associated nephropathy (HIVAN) is mostly seen in male patients and of African decent. The [[prevalence]] of HIVAN in the population of patients with African descent has been reported to be 3% to 12%.
==Epidemiology==
==Epidemiology==
===<s>Prevalence</s>===
The [[prevalence]] of HIV-associated nephropathy (HIVAN) in the population of patients with African descent has been reported to be 3% to 12%.<ref name="pmid29224373">{{cite journal| author=Menez S, Hanouneh M, McMahon BA, Fine DM, Atta MG| title=Pharmacotherapy and treatment options for HIV-associated nephropathy. | journal=Expert Opin Pharmacother | year= 2018 | volume= 19 | issue= 1 | pages= 39-48 | pmid=29224373 | doi=10.1080/14656566.2017.1416099 | pmc=6381591 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29224373  }} </ref>  
The [[prevalence]] of HIV-associated nephropathy (HIVAN) in the population of patients with African descent has been reported to be 3% to 12%.<ref name="pmid29224373">{{cite journal| author=Menez S, Hanouneh M, McMahon BA, Fine DM, Atta MG| title=Pharmacotherapy and treatment options for HIV-associated nephropathy. | journal=Expert Opin Pharmacother | year= 2018 | volume= 19 | issue= 1 | pages= 39-48 | pmid=29224373 | doi=10.1080/14656566.2017.1416099 | pmc=6381591 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29224373  }} </ref>  
<s>The prevalence of HIV-associated nephropathy in the United States and in Western European countries is estimated to range form 3 to 12 percent each year. The prevalence rate of HIV-associated neohropathy in children is estimated to be 10 to 15 percent each year. Though, there has been a decline in the incidences of HIV-associated nephropathy thank in part to the advent of HAART theraphy, which prolongs renal survival time.</s>
===<s>Incidence</s>===
<s>The incidence of HIV-associated nephropathy in the United States is estimated to be around 800 to 900 new cases per year.</s>


==Demographics==
==Demographics==

Revision as of 12:04, 30 June 2020

HIV associated nephropathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating HIV associated nephropathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

KUB X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

HIV associated nephropathy epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of HIV associated nephropathy epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on HIV associated nephropathy epidemiology and demographics

CDC on HIV associated nephropathy epidemiology and demographics

HIV associated nephropathy epidemiology and demographics in the news

Blogs on HIV associated nephropathy epidemiology and demographics

Directions to Hospitals Treating HIV associated nephropathy

Risk calculators and risk factors for HIV associated nephropathy epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2];Associate Editor(s)-in-Chief: Shakiba Hassanzadeh, MD[3]Krzysztof Wierzbicki M.D. [4]

Overview

HIV-associated nephropathy (HIVAN) is mostly seen in male patients and of African decent. The prevalence of HIVAN in the population of patients with African descent has been reported to be 3% to 12%.

Epidemiology

The prevalence of HIV-associated nephropathy (HIVAN) in the population of patients with African descent has been reported to be 3% to 12%.[1]

Demographics

Age

The average age at which patients are affected with HIV-associated nephropathy has been reported to be around 40.8 years of age in a study.[2]

Gender

HIV-associated nephropathy affects men more than women.[2]

Race

HIVAN is mostly seen in patients of African descent.[2]

References

  1. Menez S, Hanouneh M, McMahon BA, Fine DM, Atta MG (2018). "Pharmacotherapy and treatment options for HIV-associated nephropathy". Expert Opin Pharmacother. 19 (1): 39–48. doi:10.1080/14656566.2017.1416099. PMC 6381591. PMID 29224373.
  2. 2.0 2.1 2.2 Atta MG, Lucas GM, Fine DM (2008). "HIV-associated nephropathy: epidemiology, pathogenesis, diagnosis and management". Expert Rev Anti Infect Ther. 6 (3): 365–71. doi:10.1586/14787210.6.3.365. PMID 18588500.

Template:WH Template:WS